Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 6:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Heparin lock Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Distribution of Rubidium-82, Nitrogen-13 Ammonia, and Fluorine-18 Fluorodeoxyglucose in Normal Volunteers

NCT01433705
View directory record Official record
Conditions
Heart Disease
Interventions
Rb-82 Pet scans, F-18 FDG Pet scans, N-13 ammonia Pet scans, Regadenoson
Other · Drug
Lead sponsor
University of Michigan
Other
Eligibility
30 Years to 70 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2018
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 29, 2019 · Synced Sep 24, 2026, 6:45 AM EDT
Terminated Phase 1 Interventional

Micafungin Lock Therapy

NCT00809887
View directory record Official record
Conditions
Catheter-Related Fungal Infections
Interventions
Micafungin lock therapy
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
6 Months to 18 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 16, 2008 · Synced Sep 24, 2026, 6:45 AM EDT
Terminated Not applicable Interventional

Safety and Efficacy Study of Ethanol Locking to Prevent Central Line Infection in Premature Neonates

NCT01365312
View directory record Official record
Conditions
Infection Associated With Catheter, Bacteremia, Sepsis
Interventions
Ethanol lock, Heparinized saline
Drug
Lead sponsor
East Carolina University
Other
Eligibility
Up to 32 Weeks
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
1
States / cities
Greenville, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 2, 2014 · Synced Sep 24, 2026, 6:45 AM EDT
Active, not recruiting Phase 2 Interventional

Extension Study to Evaluate the Long-Term Safety and Tolerability of MBX 2109 in Patients With Hypoparathyroidism

NCT06531941
View directory record Official record
Conditions
Hypoparathyroidism
Interventions
400 µg of MBX 2109 once-weekly by subcutaneous injection, 200-1600 µg of MBX 2109 once-weekly by subcutaneous injection
Drug
Lead sponsor
MBX Biosciences
Industry
Eligibility
18 Years to 100 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
17
States / cities
Miami, Florida • Macon, Georgia • Jackson, Mississippi + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2025 · Synced Sep 24, 2026, 6:45 AM EDT
Terminated Phase 2 Interventional Results available

Allogeneic Myeloma GM-CSF Vaccine With Lenalidomide in Multiple Myeloma Patients in Complete or Near Complete Remission

NCT03376477
View directory record Official record
Conditions
Multiple Myeloma
Interventions
GM-CSF vaccine, Lenalidomide, Prevnar13, Placebo Prevnar13, Placebo GM-CSF Vaccine
Biological · Drug · Other
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 26, 2025 · Synced Sep 24, 2026, 6:45 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Intradetrusor Botulinum Toxin A for OAB Via 1 Versus 10 Injections: A Randomized Clinical Trial

NCT05308979
View directory record Official record
Conditions
Overactive Bladder, Urinary Urge Incontinence, Overactive Bladder Syndrome, Urinary Incontinence, Urge, Urge Incontinence, Urinary Urgency, Urinary Frequency
Interventions
OnabotulinumtoxinA 100 UNT [Botox]
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older · Female only
Enrollment
116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Sep 24, 2026, 6:45 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Effectiveness of Novel Nitroglycerin Based Catheter Lock Solution

NCT02577718
View directory record Official record
Conditions
Catheter-Associated Infections, Catheter-Related Infections
Interventions
Nitroglycerin-citrate-ethanol (NiCE)
Drug
Lead sponsor
Novel Anti-Infective Technologies, LLC
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 5, 2017 · Synced Sep 24, 2026, 6:45 AM EDT
Recruiting Not applicable Interventional

Reduction in Number of Botox Injections for Urgency Urinary Incontinence

NCT04731961
View directory record Official record
Conditions
Urgency Urinary Incontinence
Interventions
Standard of care (15 Botox injections), Experimental Arm (5 Botox injections)
Procedure
Lead sponsor
University of Virginia
Other
Eligibility
21 Years and older · Female only
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 27, 2025 · Synced Sep 24, 2026, 6:45 AM EDT
Completed Not applicable Interventional

The Biodistribution and Potential Diagnostic Ability of 18F FACBC in Patients With Head and Neck, Breast, and Prostate Cancer

NCT00605488
View directory record Official record
Conditions
Breast Cancer, Head and Neck Cancer, Prostate Cancer
Interventions
novel PET tracer FACBC
Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 9, 2017 · Synced Sep 24, 2026, 6:45 AM EDT
Completed Phase 1 Interventional

Randomized, Double-blind, Vehicle Controlled, Repeat Dose Comparative Study in RA Patients Managed With DMARDs

NCT04286789
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Low dose ORTD-1, Low dose vehicle control, High dose ORTD-1, High dose vehicle control
Drug
Lead sponsor
Oryn Therapeutics, LLC
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
3
States / cities
Los Angeles, California • Tustin, California • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 18, 2021 · Synced Sep 24, 2026, 6:45 AM EDT
Recruiting Phase 3 Interventional

Comparing The Safety And Efficacy Of DEFENCATH® In Reducing Central-Line Bloodstream Infections (CLABSIs) In Adults Receiving Total Parenteral Nutrition Through A Central Venous Catheter (CVC)

NCT06822426
View directory record Official record
Conditions
Central Line Associated Blood Stream Infections (CLABSI)
Interventions
(taurolidine and heparin) catheter lock solution, Heparin
Drug
Lead sponsor
CorMedix Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
17
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Doral, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Sep 24, 2026, 6:45 AM EDT
Completed Phase 3 Interventional Results available

Botulinum Toxin Versus Placebo Injections to Temporalis and Masseter Muscles

NCT03223298
View directory record Official record
Conditions
Pain, Head, Pain Syndrome, Temporomandibular Disorder, Myofascial Pain Syndrome, Myofascial Pain
Interventions
Botulinum toxin type A, 0.9% Sodium Chloride Injection
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 65 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
2
States / cities
Chicago, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 13, 2023 · Synced Sep 24, 2026, 6:45 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Feasibility Study for Fibroblast Autologous Skin Grafts

NCT01964859
View directory record Official record
Conditions
Wounds and Injuries
Interventions
autologous skin fibroblasts, Filler Product
Biological
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Sep 24, 2026, 6:45 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Acute Headache Treatment in Pregnancy: Occipital Nerve Block vs PO Acetaminophen With Caffeine

NCT03951649
View directory record Official record
Conditions
Headache, Pregnancy Related, Occipital Nerve Block
Interventions
Occipital Nerve Block
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
16 Years to 60 Years · Female only
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 19, 2023 · Synced Sep 24, 2026, 6:45 AM EDT
Completed No phase listed Observational

Post Marketing Surveillance of the CentrosFLO™ Tunneled IJ Catheter

NCT02349308
View directory record Official record
Conditions
Pain; Dialysis Catheter
Interventions
CentrosFLO Long Term Hemodialysis Catheter
Device
Lead sponsor
Merit Medical Systems, Inc.
Industry
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
7
States / cities
Tucson, Arizona • Colton, California • Los Angeles, California + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2015 · Synced Sep 24, 2026, 6:45 AM EDT
Completed Early Phase 1 Interventional

Triamcinolone Acetonide Injections in Mild-to-moderate Chronic Plaque Psoriasis With a Novel Needle-free Drug-delivery System

NCT04410237
View directory record Official record
Conditions
Psoriasis
Interventions
Med-Jet, Traditional Syringe
Device · Other
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 17, 2023 · Synced Sep 24, 2026, 6:45 AM EDT
Terminated Phase 3 Interventional Results available

Use of a Novel Catheter Lock Solution For Treatment of Hemodialysis Catheter Infections

NCT01483872
View directory record Official record
Conditions
Infection; Dialysis Catheter
Interventions
NAC/Tigecycline/Heparin combination lock solution, Standard anticoagulant (Heparin or Citrate)
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 70 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 5, 2019 · Synced Sep 24, 2026, 6:45 AM EDT
Completed No phase listed Observational

Effectiveness and Safety of Dysport® (abobotulinumtoxinA) in Paediatric Lower Limb Spasticity

NCT03017729
View directory record Official record
Conditions
Lower Limb Spasticity
Interventions
Botulinum toxin type A
Biological
Lead sponsor
Ipsen
Industry
Eligibility
2 Years to 17 Years
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
27
States / cities
Washington D.C., District of Columbia • Miami, Florida • North Palm Beach, Florida + 23 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2020 · Synced Sep 24, 2026, 6:45 AM EDT
Recruiting Phase 2 Interventional

Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast Cancer

NCT06518837
View directory record Official record
Conditions
Hormone Receptor-Positive Breast Cancer, HER2-Negative Breast Cancer
Interventions
Tirzepatide
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
7
States / cities
Elizabeth, New Jersey • Hamilton, New Jersey • Livingston, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Sep 24, 2026, 6:45 AM EDT
Completed Phase 3 Interventional Results available

Ethanol Lock Therapy for Treatment and Secondary Prophylaxis of Central Line-Associated Bloodstream Infection

NCT01472965
View directory record Official record
Conditions
Central Line-Associated Bloodstream Infection
Interventions
ethanol, heparin-saline placebo
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
6 Months to 25 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 12, 2017 · Synced Sep 24, 2026, 6:45 AM EDT
Not yet recruiting Early Phase 1 Interventional

A Novel Medical System for Quantitative Diagnosis and Personalized Precision Botulinum Neurotoxin Injection in Chronic Pelvic Pain Management

NCT05062902
View directory record Official record
Conditions
Interstitial Cystitis, Chronic Pain, Pelvic Floor; Relaxation, Pelvic Floor Disorders
Interventions
High Density Surface Electromyographic, precision botulinum neurotoxin injection guidance medical device, Botulinum Neurotoxin
Device · Drug
Lead sponsor
HillMed Inc.
Industry
Eligibility
18 Years to 60 Years · Female only
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 18, 2025 · Synced Sep 24, 2026, 6:45 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Relative Bioavailability, Safety, and Tolerability of Single-dose Sotrovimab Injection in Adults (COSMIC)

NCT05280717
View directory record Official record
Conditions
Covid19
Interventions
sotrovimab
Biological
Lead sponsor
Vir Biotechnology, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
316 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
10
States / cities
Riverside, California • Atlantis, Florida • Edgewater, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 24, 2026, 6:45 AM EDT
Terminated Early Phase 1 Interventional

Neostigmine For Snoring During DISE

NCT03316963
View directory record Official record
Conditions
Snoring
Interventions
Neostigmine Methylsulfate
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 1, 2019 · Synced Sep 24, 2026, 6:45 AM EDT
Completed Not applicable Interventional Results available

Pediatric Ethanol Lock Therapy Study.

NCT00948441
View directory record Official record
Conditions
Catheter-Related Infections
Interventions
25% ethanol, heparin lock
Drug · Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
6 Months to 21 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 17, 2016 · Synced Sep 24, 2026, 6:45 AM EDT